

National Health (Continued Dispensing – Emergency Measure) Determination 2023

PB 137 of 2023

made under subsection 89A(3) of the

National Health Act 1953

**Compilation No. 1**

**Compilation date:** 29 February 2024

**Includes amendments:** F2024L00239

**Registered:** 23 April 2024

**About this compilation**

**This compilation**

This is a compilation of the *National Health (Continued Dispensing – Emergency Measure) Determination 2023* that shows the text of the law as amended and in force on 29 February 2024 (the ***compilation date***).

The notes at the end of this compilation (the ***endnotes***) include information about amending laws and the amendment history of provisions of the compiled law.

**Uncommenced amendments**

The effect of uncommenced amendments is not shown in the text of the compiled law. Any uncommenced amendments affecting the law are accessible on the Register (www.legislation.gov.au). The details of amendments made up to, but not commenced at, the compilation date are underlined in the endnotes. For more information on any uncommenced amendments, see the Register for the compiled law.

**Application, saving and transitional provisions for provisions and amendments**

If the operation of a provision or amendment of the compiled law is affected by an application, saving or transitional provision that is not included in this compilation, details are included in the endnotes.

**Editorial changes**

For more information about any editorial changes made in this compilation, see the endnotes.

**Modifications**

If the compiled law is modified by another law, the compiled law operates as modified but the modification does not amend the text of the law. Accordingly, this compilation does not show the text of the compiled law as modified. For more information on any modifications, see the Register for the compiled law.

**Self‑repealing provisions**

If a provision of the compiled law has been repealed in accordance with a provision of the law, details are included in the endnotes.

Contents

Part 1—Preliminary 1

1.01 Name 1

1.02 Commencement 1

1.03 Authority 1

1.04 Schedule 2 1

1.05 Definitions 1

1.06 Purpose 2

1.07 Operation of this instrument 2

Part 2—Pharmaceutical benefits that may be supplied without a prescription 4

2.01 Pharmaceutical benefits covered by this instrument 4

Part 3—Specified conditions for supplying pharmaceutical benefits without a prescription 5

3.01 General 5

3.02 Condition—unable to obtain prescription 5

3.03 Condition—previous supply of pharmaceutical benefit 5

3.04 Condition—stability of therapy 5

3.05 Condition—prior clinical review by PBS prescriber 5

3.06 Condition—prescription for last supply of pharmaceutical benefit 6

3.07 Condition—no continued dispensing in previous 12 months 6

3.08 Condition—declaration for supply of pharmaceutical benefit 6

3.09 Condition—maximum quantity of supply 6

3.10 Condition—preparing and recording information 6

Schedule 1—Pharmaceutical benefits that may be supplied without a prescription 8

1 Pharmaceutical benefits that may be supplied without a prescription by an approved pharmacist 8

Schedule 2—Repeals 34

National Health (Continued Dispensing – Emergency Measure) Determination 2023 34

Endnotes 35

Endnote 1—About the endnotes 35

Endnote 2—Abbreviation key 36

Endnote 3—Legislation history 37

Endnote 4—Amendment history 38

Part 1—Preliminary

1.01 Name

(1) This instrument is the *National Health (Continued Dispensing – Emergency Measure) Determination 2023*.

(2) This instrument may also be cited as PB 137 of 2023.

1.02 Commencement

(1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

| Commencement information | | |
| --- | --- | --- |
| Column 1 | Column 2 | Column 3 |
| Provisions | Commencement | Date/Details |
| 1. Parts 1 to 4 and Schedule 1 | Immediately after this instrument is registered | 4.06 pm (A.C.T.) 21 December 2023 |
| 2. Schedule 2 | At the end of 31 March 2024. | 31 March 2024 |

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

(2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

1.03 Authority

This instrument is made under subsection 89A(3) of the *National Health Act 1953*.

1.04 Schedule 2

Each instrument that is specified in Schedule 2 to this instrument is amended or repealed as set out in the applicable items in that Schedule, and any other item in that Schedule has effect according to its terms.

1.05 Definitions

(1) In this instrument:

***Act*** means the *National Health Act 1953*.

***electronic prescription*** has the meaning given by subsection 5(1) of the *National Health (Pharmaceutical Benefits) Regulations 2017*.

***increased maximum quantity***, for a pharmaceutical item, means a quantity or number of units that has been determined under paragraph 85A(2)(a) of the Act as the maximum quantity or number of units of the pharmaceutical item in the pharmaceutical benefit that may, for a relevant purpose, be directed in a prescription to be supplied on any one occasion.

***patient***: see subsection 3.01(1).

***purposes code*** has the meaning given by the *National Health (Listing of Pharmaceutical Benefits) Instrument 2012*.

***relevant purpose***,for a pharmaceutical benefit, means a purpose, mentioned in Schedule 4 of the *National Health (Listing of Pharmaceutical Benefits) Instrument 2012* for a purposes code specified in Schedule 1 of that instrument for the pharmaceutical benefit, that includes the phrase “The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient”.

***requested supply***: see subsection 3.01(1).

(2) A reference in this instrument to a pharmaceutical benefit having a drug is a reference to the pharmaceutical benefit having the drug or medicinal preparation referred to in paragraph (a) of the definition of pharmaceutical benefit in subsection 84(1) of the Act in relation to the pharmaceutical benefit.

(3) An expression that is used in this instrument and in Part VII of the Act has the same meaning in this instrument as it has in that Part.

Examples:

(a) approved pharmacist;

(b) listed brand;

(c) PBS prescriber;

(d) pharmaceutical benefit;

(e) pharmaceutical item;

(f) prescriber bag provisions;

(g) Schedule equivalent.

1.06 Purpose

The purpose of this instrument is to determine:

(a) pharmaceutical benefits that may be supplied by an approved pharmacist without a prescription; and

(b) the conditions that must be satisfied when making a supply of those pharmaceutical benefits.

1.07 Operation of this instrument

(1)  This instrument does not apply to the following supplies:

(a) the supply of a pharmaceutical benefit that is not generally available for supply under Part VII of the Act; or

(b) the supply of a pharmaceutical benefit in accordance with a special arrangement made under section 100 of the Act; or

(c)   the supply of a pharmaceutical benefit under a prescriber bag provision.

(2) A pharmaceutical benefit is ***generally available for supply under Part VII of the Act***if:

(a)   it does not contain a drug that is subject to a declaration under subsection 85(2A) of the Act; or

(b)   it is not subject to a determination under paragraph 85(8)(a) of the Act; or

(c)   for a pharmaceutical benefit in relation to which a determination under paragraph 85(8)(b) of the Act has been made about the circumstances in which the benefit can only be supplied under a special arrangement under section 100 of the Act ‑ the supply is not in those circumstances.

Part 2—Pharmaceutical benefits that may be supplied without a prescription

2.01 Pharmaceutical benefits covered by this instrument

For the purposes of paragraph 89A(3)(a) of the Act, the pharmaceutical benefits covered by an item in the table in Schedule 1 (being pharmaceutical benefits that have the drug specified in the table item) are determined to be pharmaceutical benefits that may be supplied by an approved pharmacist without a prescription for the supply.

Part 3—Specified conditions for supplying pharmaceutical benefits without a prescription

3.01 General

(1) For the purposes of paragraph 89A(3)(b) of the Act, the conditions specified in this Part are determined to be the conditions that must be satisfied when making a supply (the ***requested supply***) of a pharmaceutical benefit to a person (the ***patient***) requesting the supply without a prescription in accordance with subsection 89A(1) of the Act.

(2) In this Part:

(a) a reference to the PBS prescriber is a reference to the PBS prescriber who most recently prescribed the supply of the pharmaceutical benefit to the patient; and

(b) a reference to “the pharmaceutical benefit” in sections 3.03, 3.05, 3.06 and 3.07 includes a reference to a pharmaceutical benefit that is a Schedule equivalent.

3.02 Condition—unable to obtain prescription

The approved pharmacist must be satisfied of either or both of the following:

(a) the PBS prescriber is unable to be contacted;

(b) the PBS prescriber is unable to provide an electronic prescription.

3.03 Condition—previous supply of pharmaceutical benefit

The approved pharmacist must be satisfied that:

(a) the patient has previously been supplied the pharmaceutical benefit on the basis of a prescription from a PBS prescriber; and

(b) the PBS prescriber prescribed the supply of the pharmaceutical benefit for the patient in at least one of the circumstances determined for that pharmaceutical benefit under paragraph 85(7)(b) of the Act.

Note: The circumstances determined under paragraph 85(7)(b) of the Act relate to pharmaceutical benefits that are relevant pharmaceutical benefits under section 88A of the Act.

3.04 Condition—stability of therapy

The approved pharmacist must be satisfied that the patient’s therapy is stable.

3.05 Condition—prior clinical review by PBS prescriber

The approved pharmacist must be satisfied that:

(a) the patient has been taking the pharmaceutical benefit regularly for an uninterrupted period; and

(b) since the start of that period, the PBS prescriber has assessed the patient’s condition and decided that there is a need for ongoing treatment with the pharmaceutical benefit.

Note: See paragraph 3.01(2)(a) for references to the PBS prescriber.

3.06 Condition—prescription for last supply of pharmaceutical benefit

The approved pharmacist must be satisfied that the patient had a valid prescription under Part VII of the Act for the last supply of the pharmaceutical benefit to the patient before the requested supply.

3.07 Condition—no continued dispensing in previous 12 months

The approved pharmacist must be satisfied that the patient was not supplied with the pharmaceutical benefit under subsection 89A(1) of the Act in the 12 months before the requested supply.

3.08 Condition—declaration for supply of pharmaceutical benefit

The approved pharmacist must ensure that the patient, or an agent of the patient (other than the approved pharmacist), signs a declaration acknowledging that the patient is being supplied with the pharmaceutical benefit without the presentation of a valid prescription under Part VII of the Act.

3.09 Condition—maximum quantity of supply

(1) The approved pharmacist must supply a maximum quantity or number of units of the pharmaceutical item in the pharmaceutical benefit determined under paragraph 85A(2)(a) of the Act.

(2)  However, where an increased maximum quantity has been determined for the pharmaceutical item in the pharmaceutical benefit, the approved pharmacist may only supply that increased maximum quantity if the last supply to the patient of the pharmaceutical benefit, or a pharmaceutical benefit that is Schedule equivalent, was on the basis of a prescription written for:

                     (a)  a relevant purpose for the pharmaceutical benefit; or

                     (b)  a relevant purpose for a pharmaceutical benefit that is Schedule equivalent to the pharmaceutical benefit.

3.10 Condition—preparing and recording information

(1) The approved pharmacist must, when the pharmaceutical benefit is supplied:

(a) record the information that the pharmacist used to support the pharmacist’s decision to supply the pharmaceutical benefit; and

(b) prepare information about the supply to the patient that the pharmacist will send to the PBS prescriber.

(2) The information that must be recorded and prepared under subsection (1) must include the following:

(a) a statement that the pharmaceutical benefit supplied is a pharmaceutical benefit covered by Schedule 1;

(b) a statement that the conditions mentioned in sections 3.02 to 3.05 are satisfied;

(c) a statement that the approved pharmacist is satisfied that the pharmaceutical benefit needs to be supplied to the patient to facilitate continuity of treatment.

Schedule 1—Pharmaceutical benefits that may be supplied without a prescription

Note: See section 2.01.

1 Pharmaceutical benefits that may be supplied without a prescription by an approved pharmacist

| **Item** | **Listed drug** |
| --- | --- |
| 1 | Abatacept |
| 2 | Abemaciclib |
| 3 | Abiraterone |
| 4 | Abiraterone and methylprednisolone |
| 5 | Acalabrutinib |
| 6 | Acamprosate |
| 7 | Acarbose |
| 8 | Acetazolamide |
| 9 | Aciclovir |
| 10 | Acitretin |
| 11 | Aclidinium |
| 12 | Aclidinium with formoterol |
| 13 | Adalimumab |
| 14 | Adapalene with benzoyl peroxide |
| 15 | Adrenaline (epinephrine) |
| 16 | Afatinib |
| 17 | Aflibercept |
| 18 | Albendazole |
| 19 | Alectinib |
| 20 | Alendronic acid |
| 21 | Alendronic acid with colecalciferol |
| 22 | Alirocumab |
| 23 | Allopurinol |
| 24 | Alogliptin |
| 25 | Alogliptin with metformin |
| 26 | Alprazolam |
| 27 | Amantadine |
| 28 | Amifampridine |
| 29 | Amino acid formula supplemented with prebiotics, probiotics and long chain polyunsaturated fatty acids |
| 30 | Amino acid formula with carbohydrate without phenylalanine |
| 31 | Amino acid formula with carbohydrate, vitamins, minerals and trace elements without phenylalanine |
| 32 | Amino acid formula with fat, carbohydrate without methionine |
| 33 | Amino acid formula with fat, carbohydrate without phenylalanine |
| 34 | Amino acid formula with fat, carbohydrate without phenylalanine and tyrosine |
| 35 | Amino acid formula with fat, carbohydrate without valine, leucine and isoleucine |
| 36 | Amino acid formula with fat, carbohydrate, vitamins, minerals and trace elements without phenylalanine |
| 37 | Amino acid formula with fat, carbohydrate, vitamins, minerals and trace elements without phenylalanine and tyrosine |
| 38 | Amino acid formula with fat, carbohydrate, vitamins, minerals and trace elements without phenylalanine and tyrosine, and supplemented with docosahexanoic acid |
| 39 | Amino acid formula with fat, carbohydrate, vitamins, minerals, and trace elements, without methionine and supplemented with docosahexanoic acid |
| 40 | Amino acid formula with fat, carbohydrate, vitamins, minerals, trace elements and medium chain triglycerides |
| 41 | Amino acid formula with vitamins and minerals without lysine and low in tryptophan |
| 42 | Amino acid formula with vitamins and minerals without methionine |
| 43 | Amino acid formula with vitamins and minerals without methionine, threonine and valine and low in isoleucine |
| 44 | Amino acid formula with vitamins and minerals without phenylalanine |
| 45 | Amino acid formula with vitamins and minerals without phenylalanine and tyrosine |
| 46 | Amino acid formula with vitamins and minerals without valine, leucine and isoleucine |
| 47 | Amino acid formula with vitamins and minerals without valine, leucine and isoleucine with fat, carbohydrate and trace elements and supplemented with docosahexanoic acid |
| 48 | Amino acid formula with vitamins and minerals, low phenylalanine and supplemented with docosahexaenoic acid and arachidonic acid |
| 49 | Amino acid formula with vitamins, minerals and long chain polyunsaturated fatty acids without phenylalanine |
| 50 | Amino acid formula without phenylalanine |
| 51 | Amino acid formula without valine, leucine and isoleucine |
| 52 | Amino acid synthetic formula supplemented with long chain polyunsaturated fatty acids |
| 53 | Amino acid synthetic formula supplemented with long chain polyunsaturated fatty acids and medium chain triglycerides |
| 54 | Amino acids‑synthetic, formula |
| 55 | Amiodarone |
| 56 | Amisulpride |
| 57 | Amitriptyline |
| 58 | Amlodipine |
| 59 | Amlodipine with atorvastatin |
| 60 | Amlodipine with valsartan |
| 61 | Amlodipine with valsartan and hydrochlorothiazide |
| 62 | Amoxicillin |
| 63 | Amoxicillin with clavulanic acid |
| 64 | Amphotericin B |
| 65 | Amylopectin, modified long chain |
| 66 | Anastrozole |
| 67 | Apalutamide |
| 68 | Apixaban |
| 69 | Apomorphine |
| 70 | Apremilast |
| 71 | Aprepitant |
| 72 | Arachidonic acid and docosahexaenoic acid with carbohydrate |
| 73 | Arginine with carbohydrate |
| 74 | Aripiprazole |
| 75 | Armodafinil |
| 76 | Artemether with lumefantrine |
| 77 | Asciminib |
| 78 | Asenapine |
| 79 | Aspirin |
| 80 | Atenolol |
| 81 | Atomoxetine |
| 82 | Atorvastatin |
| 83 | Atovaquone |
| 84 | Atovaquone with proguanil |
| 85 | Atropine |
| 86 | Auranofin |
| 87 | Axitinib |
| 88 | Azacitidine |
| 89 | Azathioprine |
| 90 | Azithromycin |
| 91 | Baclofen |
| 92 | Balsalazide |
| 93 | Baricitinib |
| 94 | Beclometasone |
| 95 | Beclometasone with formoterol |
| 96 | Beclometasone with formoterol and glycopyrronium |
| 97 | Benzathine benzylpenicillin |
| 98 | Benzatropine |
| 99 | Benzydamine |
| 100 | Benzylpenicillin |
| 101 | Betaine |
| 102 | Betamethasone |
| 103 | Betaxolol |
| 104 | Bethanechol |
| 105 | Bicalutamide |
| 106 | Bimatoprost |
| 107 | Bimatoprost with timolol |
| 108 | Bimekizumab |
| 109 | Binimetinib |
| 110 | Bisacodyl |
| 111 | Bisoprolol |
| 112 | Bivalirudin |
| 113 | Brexpiprazole |
| 114 | Brigatinib |
| 115 | Brimonidine |
| 116 | Brimonidine with timolol |
| 117 | Brinzolamide |
| 118 | Brinzolamide with brimonidine |
| 119 | Brinzolamide with timolol |
| 120 | Brivaracetam |
| 121 | Brolucizumab |
| 122 | Bromocriptine |
| 123 | Budesonide |
| 124 | Budesonide with formoterol |
| 125 | Budesonide with glycopyrronium and formoterol |
| 126 | Buprenorphine |
| 127 | Bupropion |
| 128 | Busulfan |
| 129 | Cabergoline |
| 130 | Cabozantinib |
| 131 | Calcipotriol with betamethasone |
| 132 | Calcitonin salmon |
| 133 | Calcitriol |
| 134 | Calcium |
| 135 | Candesartan |
| 136 | Candesartan with hydrochlorothiazide |
| 137 | Cannabidiol |
| 138 | Capecitabine |
| 139 | Captopril |
| 140 | Carbamazepine |
| 141 | Carbimazole |
| 142 | Carbohydrate, fat, vitamins, minerals and trace elements |
| 143 | Carbohydrate, fat, vitamins, minerals and trace elements and supplemented with arachidonic acid and docosahexaenoic acid |
| 144 | Carbomer |
| 145 | Carbomer 974 |
| 146 | Cariprazine |
| 147 | Carmellose |
| 148 | Carmellose with glycerin |
| 149 | Carmustine |
| 150 | Carvedilol |
| 151 | Cefaclor |
| 152 | Cefalexin |
| 153 | Cefazolin |
| 154 | Cefepime |
| 155 | Cefotaxime |
| 156 | Ceftriaxone |
| 157 | Cefuroxime |
| 158 | Celecoxib |
| 159 | Ceritinib |
| 160 | Certolizumab pegol |
| 161 | Chlorambucil |
| 162 | Chloramphenicol |
| 163 | Chlorpromazine |
| 164 | Chlortalidone |
| 165 | Choriogonadotropin alfa |
| 166 | Chorionic gonadotrophin |
| 167 | Ciclesonide |
| 168 | Ciclosporin |
| 169 | Cinacalcet |
| 170 | Ciprofloxacin |
| 171 | Citalopram |
| 172 | Citrulline |
| 173 | Citrulline with carbohydrate |
| 174 | Cladribine |
| 175 | Clarithromycin |
| 176 | Clindamycin |
| 177 | Clobetasol |
| 178 | Clomifene |
| 179 | Clomipramine |
| 180 | Clonazepam |
| 181 | Clonidine |
| 182 | Clopidogrel |
| 183 | Clopidogrel with aspirin |
| 184 | Cobimetinib |
| 185 | Codeine |
| 186 | Codeine with paracetamol |
| 187 | Colchicine |
| 188 | Colestyramine |
| 189 | Cortisone |
| 190 | Crizotinib |
| 191 | Cyclophosphamide |
| 192 | Cyproterone |
| 193 | Dabigatran etexilate |
| 194 | Dabrafenib |
| 195 | Dantrolene |
| 196 | Dapagliflozin |
| 197 | Dapagliflozin with metformin |
| 198 | Dapsone |
| 199 | Daratumumab |
| 200 | Darolutamide |
| 201 | Dasatinib |
| 202 | Decitabine with cedazuridine |
| 203 | Degarelix |
| 204 | Denosumab |
| 205 | Desmopressin |
| 206 | Desvenlafaxine |
| 207 | Deucravacitinib |
| 208 | Dexamethasone |
| 209 | Dexamethasone with framycetin and gramicidin |
| 210 | Dexamfetamine |
| 211 | Diazepam |
| 212 | Diclofenac |
| 213 | Dicloxacillin |
| 214 | Digoxin |
| 215 | Diltiazem |
| 216 | Dimethyl fumarate |
| 217 | Diphenoxylate with atropine |
| 218 | Diphtheria and tetanus vaccine, adsorbed, diluted for adult use |
| 219 | Diroximel fumarate |
| 220 | Disopyramide |
| 221 | Domperidone |
| 222 | Donepezil |
| 223 | Dorzolamide |
| 224 | Dorzolamide with timolol |
| 225 | Dosulepin |
| 226 | Doxycycline |
| 227 | Dulaglutide |
| 228 | Duloxetine |
| 229 | Dupilumab |
| 230 | Dutasteride |
| 231 | Dutasteride with tamsulosin |
| 232 | Electrolyte replacement, oral |
| 233 | Eletriptan |
| 234 | Empagliflozin |
| 235 | Empagliflozin with linagliptin |
| 236 | Empagliflozin with metformin |
| 237 | Enalapril |
| 238 | Enalapril with hydrochlorothiazide |
| 239 | Encorafenib |
| 240 | Enoxaparin |
| 241 | Entacapone |
| 242 | Entrectinib |
| 243 | Enzalutamide |
| 244 | Eplerenone |
| 245 | Eprosartan |
| 246 | Eprosartan with hydrochlorothiazide |
| 247 | Eptinezumab |
| 248 | Erlotinib |
| 249 | Erythromycin |
| 250 | Escitalopram |
| 251 | Esomeprazole |
| 252 | Esomeprazole and clarithromycin and amoxicillin |
| 253 | Essential amino acids formula |
| 254 | Essential amino acids formula with minerals and vitamin c |
| 255 | Essential amino acids formula with vitamins and minerals |
| 256 | Estradiol |
| 257 | Estradiol and estradiol with dydrogesterone |
| 258 | Estradiol and estradiol with norethisterone |
| 259 | Estradiol with norethisterone |
| 260 | Estriol |
| 261 | Etanercept |
| 262 | Ethosuximide |
| 263 | Etonogestrel |
| 264 | Etoposide |
| 265 | Everolimus |
| 266 | Evolocumab |
| 267 | Exemestane |
| 268 | Ezetimibe |
| 269 | Ezetimibe and rosuvastatin |
| 270 | Ezetimibe with atorvastatin |
| 271 | Ezetimibe with simvastatin |
| 272 | Famciclovir |
| 273 | Famotidine |
| 274 | Faricimab |
| 275 | Febuxostat |
| 276 | Felodipine |
| 277 | Fenofibrate |
| 278 | Fentanyl |
| 279 | Ferric carboxymaltose |
| 280 | Ferric derisomaltose |
| 281 | Ferrous fumarate |
| 282 | Ferrous fumarate with folic acid |
| 283 | Ferrous sulfate |
| 284 | Finerenone |
| 285 | Fingolimod |
| 286 | Flecainide |
| 287 | Flucloxacillin |
| 288 | Fluconazole |
| 289 | Fludarabine |
| 290 | Fludrocortisone |
| 291 | Fluorometholone |
| 292 | Fluoxetine |
| 293 | Flupentixol decanoate |
| 294 | Flutamide |
| 295 | Fluticasone furoate |
| 296 | Fluticasone furoate with umeclidinium and vilanterol |
| 297 | Fluticasone furoate with vilanterol |
| 298 | Fluticasone propionate |
| 299 | Fluticasone propionate with formoterol |
| 300 | Fluticasone propionate with salmeterol |
| 301 | Fluvastatin |
| 302 | Fluvoxamine |
| 303 | Folic acid |
| 304 | Folinic acid |
| 305 | Follitropin alfa |
| 306 | Follitropin beta |
| 307 | Fondaparinux |
| 308 | Formoterol |
| 309 | Fosaprepitant |
| 310 | Fosinopril |
| 311 | Fosinopril with hydrochlorothiazide |
| 312 | Fosnetupitant with palonosetron |
| 313 | Framycetin |
| 314 | Fremanezumab |
| 315 | Fulvestrant |
| 316 | Furosemide |
| 317 | Fusidic acid |
| 318 | Gabapentin |
| 319 | Galantamine |
| 320 | Galcanezumab |
| 321 | Gefitinib |
| 322 | Gemfibrozil |
| 323 | Gentamicin |
| 324 | Gilteritinib |
| 325 | Glatiramer |
| 326 | Glecaprevir with pibrentasvir |
| 327 | Glibenclamide |
| 328 | Gliclazide |
| 329 | Glimepiride |
| 330 | Glipizide |
| 331 | Glucagon |
| 332 | Glucose and ketone indicator‑urine |
| 333 | Glucose indicator‑urine |
| 334 | Glyceryl trinitrate |
| 335 | Glycine with carbohydrate |
| 336 | Glycomacropeptide and essential amino acid formula with vitamins, minerals, and low in tyrosine and phenylalanine |
| 337 | Glycomacropeptide and essential amino acids with vitamins and minerals |
| 338 | Glycomacropeptide formula with long chain polyunsaturated fatty acids and docosahexaenoic acid and low in phenylalanine |
| 339 | Glycopyrronium |
| 340 | Golimumab |
| 341 | Goserelin |
| 342 | Goserelin and bicalutamide |
| 343 | Granisetron |
| 344 | Griseofulvin |
| 345 | Guanfacine |
| 346 | Guselkumab |
| 347 | Haloperidol |
| 348 | Haloperidol decanoate |
| 349 | Heparin |
| 350 | High fat formula with vitamins, minerals and trace elements and low in protein and carbohydrate |
| 351 | Hyaluronic acid |
| 352 | Hydrochlorothiazide |
| 353 | Hydrochlorothiazide with amiloride |
| 354 | Hydrocortisone |
| 355 | Hydromorphone |
| 356 | Hydroxocobalamin |
| 357 | Hydroxycarbamide |
| 358 | Hydroxychloroquine |
| 359 | Hydroxyethyl starch 130/0.4 |
| 360 | Hyoscine |
| 361 | Hypromellose |
| 362 | Hypromellose with carbomer 980 |
| 363 | Hypromellose with dextran |
| 364 | Ibandronic acid |
| 365 | Ibrutinib |
| 366 | Ibuprofen |
| 367 | Icatibant |
| 368 | Idelalisib |
| 369 | Imatinib |
| 370 | Imipramine |
| 371 | Imiquimod |
| 372 | Indacaterol |
| 373 | Indacaterol with glycopyrronium |
| 374 | Indacaterol with glycopyrronium and mometasone |
| 375 | Indacaterol with mometasone |
| 376 | Indapamide |
| 377 | Indometacin |
| 378 | Infliximab |
| 379 | Insect allergen extract‑honey bee venom |
| 380 | Insect allergen extract‑paper wasp venom |
| 381 | Insect allergen extract‑yellow jacket venom |
| 382 | Insulin aspart |
| 383 | Insulin aspart with insulin aspart protamine suspension |
| 384 | Insulin degludec with insulin aspart |
| 385 | Insulin detemir |
| 386 | Insulin glargine |
| 387 | Insulin glulisine |
| 388 | Insulin isophane |
| 389 | Insulin lispro |
| 390 | Insulin lispro with insulin lispro protamine suspension |
| 391 | Insulin neutral |
| 392 | Insulin neutral with insulin isophane |
| 393 | Interferon beta‑1b |
| 394 | Ipratropium |
| 395 | Irbesartan |
| 396 | Irbesartan with hydrochlorothiazide |
| 397 | Iron polymaltose complex |
| 398 | Iron sucrose |
| 399 | Isoleucine with carbohydrate |
| 400 | Isoniazid |
| 401 | Isosorbide dinitrate |
| 402 | Isosorbide mononitrate |
| 403 | Isotretinoin |
| 404 | Itraconazole |
| 405 | Ivabradine |
| 406 | Ivermectin |
| 407 | Ixekizumab |
| 408 | Ketoconazole |
| 409 | Ketoprofen |
| 410 | Labetalol |
| 411 | Lacosamide |
| 412 | Lamotrigine |
| 413 | Lanadelumab |
| 414 | Lansoprazole |
| 415 | Lanthanum |
| 416 | Lapatinib |
| 417 | Larotrectinib |
| 418 | Latanoprost |
| 419 | Latanoprost with timolol |
| 420 | Leflunomide |
| 421 | Lenvatinib |
| 422 | Lercanidipine |
| 423 | Lercanidipine with enalapril |
| 424 | Letrozole |
| 425 | Leuprorelin |
| 426 | Leuprorelin and bicalutamide |
| 427 | Levetiracetam |
| 428 | Levodopa with benserazide |
| 429 | Levodopa with carbidopa |
| 430 | Levodopa with carbidopa and entacapone |
| 431 | Levonorgestrel |
| 432 | Levonorgestrel with ethinylestradiol |
| 433 | Levothyroxine |
| 434 | Lidocaine |
| 435 | Linagliptin |
| 436 | Linagliptin with metformin |
| 437 | Lincomycin |
| 438 | Liothyronine |
| 439 | Lisdexamfetamine |
| 440 | Lisinopril |
| 441 | Lithium |
| 442 | Loperamide |
| 443 | Lorlatinib |
| 444 | Lurasidone |
| 445 | Macrogol 3350 |
| 446 | Magnesium |
| 447 | Medroxyprogesterone |
| 448 | Mefenamic acid |
| 449 | Meloxicam |
| 450 | Melphalan |
| 451 | Memantine |
| 452 | Mercaptopurine |
| 453 | Mesalazine |
| 454 | Mesna |
| 455 | Metformin |
| 456 | Methadone |
| 457 | Methenamine |
| 458 | Methotrexate |
| 459 | Methyldopa |
| 460 | Methylnaltrexone |
| 461 | Methylphenidate |
| 462 | Methylprednisolone |
| 463 | Metoclopramide |
| 464 | Metoprolol |
| 465 | Metoprolol succinate |
| 466 | Metronidazole |
| 467 | Mianserin |
| 468 | Miconazole |
| 469 | Mifepristone and misoprostol |
| 470 | Milk powder ‑‑ synthetic |
| 471 | Milk protein and fat formula with vitamins and minerals ‑‑ carbohydrate free |
| 472 | Minocycline |
| 473 | Minoxidil |
| 474 | Mirtazapine |
| 475 | Moclobemide |
| 476 | Modafinil |
| 477 | Molnupiravir |
| 478 | Mometasone |
| 479 | Montelukast |
| 480 | Morphine |
| 481 | Moxonidine |
| 482 | Mupirocin |
| 483 | Mycobacterium bovis (Bacillus Calmette and Guerin (BCG)) Danish 1331 strain |
| 484 | Mycobacterium bovis (Bacillus Calmette and Guerin), Tice strain |
| 485 | Mycophenolic acid |
| 486 | Nafarelin |
| 487 | Naloxone |
| 488 | Naltrexone |
| 489 | Naproxen |
| 490 | Naratriptan |
| 491 | Nebivolol |
| 492 | Netupitant with Palonosetron |
| 493 | Nicorandil |
| 494 | Nicotine |
| 495 | Nifedipine |
| 496 | Nilotinib |
| 497 | Nintedanib |
| 498 | Niraparib |
| 499 | Nirmatrelvir and ritonavir |
| 500 | Nitrazepam |
| 501 | Nitrofurantoin |
| 502 | Nizatidine |
| 503 | Norethisterone |
| 504 | Norethisterone with ethinylestradiol |
| 505 | Norfloxacin |
| 506 | Nortriptyline |
| 507 | Nystatin |
| 508 | Obeticholic acid |
| 509 | Ofatumumab |
| 510 | Ofloxacin |
| 511 | Olanzapine |
| 512 | Olaparib |
| 513 | Olmesartan |
| 514 | Olmesartan with amlodipine |
| 515 | Olmesartan with amlodipine and hydrochlorothiazide |
| 516 | Olmesartan with hydrochlorothiazide |
| 517 | Olsalazine |
| 518 | Omeprazole |
| 519 | Ondansetron |
| 520 | Opicapone |
| 521 | Osimertinib |
| 522 | Oxazepam |
| 523 | Oxcarbazepine |
| 524 | Oxprenolol |
| 525 | Oxybutynin |
| 526 | Oxycodone |
| 527 | Oxycodone with naloxone |
| 528 | Ozanimod |
| 529 | Palbociclib |
| 530 | Paliperidone |
| 531 | Palonosetron |
| 532 | Pamidronic acid |
| 533 | Pancreatic extract |
| 534 | Pantoprazole |
| 535 | Paracetamol |
| 536 | Paraffin |
| 537 | Paraffin with retinol palmitate |
| 538 | Paroxetine |
| 539 | Patiromer |
| 540 | Pazopanib |
| 541 | Peginterferon alfa‑2a |
| 542 | Peginterferon beta‑1a |
| 543 | Penicillamine |
| 544 | Perampanel |
| 545 | Perfluorohexyloctane |
| 546 | Perhexiline |
| 547 | Periciazine |
| 548 | Perindopril |
| 549 | Perindopril with amlodipine |
| 550 | Perindopril with indapamide |
| 551 | Permethrin |
| 552 | Phenelzine |
| 553 | Phenobarbital |
| 554 | Phenoxybenzamine |
| 555 | Phenoxymethylpenicillin |
| 556 | Phenylalanine with carbohydrate |
| 557 | Phenytoin |
| 558 | Pilocarpine |
| 559 | Pimecrolimus |
| 560 | Pioglitazone |
| 561 | Pirfenidone |
| 562 | Piroxicam |
| 563 | Pizotifen |
| 564 | Polyethylene glycol 400 with propylene glycol |
| 565 | Poly‑l‑lactic acid |
| 566 | Ponatinib |
| 567 | Posaconazole |
| 568 | Potassium chloride |
| 569 | Potassium chloride with potassium bicarbonate |
| 570 | Pramipexole |
| 571 | Pravastatin |
| 572 | Praziquantel |
| 573 | Prazosin |
| 574 | Prednisolone |
| 575 | Prednisolone with phenylephrine |
| 576 | Prednisone |
| 577 | Pregabalin |
| 578 | Primidone |
| 579 | Probenecid |
| 580 | Procaine benzylpenicillin |
| 581 | Prochlorperazine |
| 582 | Progesterone |
| 583 | Promethazine |
| 584 | Propantheline |
| 585 | Propranolol |
| 586 | Propylthiouracil |
| 587 | Protein formula with amino acids, carbohydrates, vitamins and minerals without phenylalanine, and supplemented with docosahexaenoic acid |
| 588 | Protein formula with carbohydrate, fat, vitamins and minerals |
| 589 | Protein formula with vitamins and minerals, and low in potassium, phosphorus, calcium, chloride and vitamin A |
| 590 | Protein hydrolysate formula with medium chain triglycerides |
| 591 | Pyrantel |
| 592 | Pyridostigmine |
| 593 | Quetiapine |
| 594 | Quinagolide |
| 595 | Quinapril |
| 596 | Quinapril with hydrochlorothiazide |
| 597 | Quinine |
| 598 | Rabeprazole |
| 599 | Raloxifene |
| 600 | Ramipril |
| 601 | Ramipril with felodipine |
| 602 | Ranibizumab |
| 603 | Ranitidine |
| 604 | Rasagiline |
| 605 | Reboxetine |
| 606 | Ribavirin |
| 607 | Ribociclib |
| 608 | Rifampicin |
| 609 | Rifaximin |
| 610 | Riluzole |
| 611 | Ripretinib |
| 612 | Risankizumab |
| 613 | Risedronic acid |
| 614 | Risperidone |
| 615 | Rivaroxaban |
| 616 | Rivastigmine |
| 617 | Rizatriptan |
| 618 | Romosozumab |
| 619 | Rosuvastatin |
| 620 | Rotigotine |
| 621 | Roxithromycin |
| 622 | Ruxolitinib |
| 623 | Sacubitril with valsartan |
| 624 | Safinamide |
| 625 | Salbutamol |
| 626 | Salmeterol |
| 627 | Sapropterin |
| 628 | Saxagliptin |
| 629 | Saxagliptin with dapagliflozin |
| 630 | Saxagliptin with metformin |
| 631 | Secukinumab |
| 632 | Selegiline |
| 633 | Semaglutide |
| 634 | Sertraline |
| 635 | Sevelamer |
| 636 | Silver sulfadiazine |
| 637 | Simvastatin |
| 638 | Siponimod |
| 639 | Sirolimus |
| 640 | Sitagliptin |
| 641 | Sitagliptin with metformin |
| 642 | Sodium acid phosphate |
| 643 | Sodium bicarbonate |
| 644 | Sodium phenylbutyrate |
| 645 | Sofosbuvir with velpatasvir |
| 646 | Sofosbuvir with velpatasvir and voxilaprevir |
| 647 | Sonidegib |
| 648 | Sorafenib |
| 649 | Sorbitol with sodium citrate dihydrate and sodium lauryl sulfoacetate |
| 650 | Sotalol |
| 651 | Soy lecithin |
| 652 | Soy protein and fat formula with vitamins and minerals ‑‑ carbohydrate free |
| 653 | Spironolactone |
| 654 | Stiripentol |
| 655 | Sucroferric oxyhydroxide |
| 656 | Sulfasalazine |
| 657 | Sulthiame |
| 658 | Sumatriptan |
| 659 | Sunitinib |
| 660 | Tacrolimus |
| 661 | Tafluprost |
| 662 | Tamoxifen |
| 663 | Tapentadol |
| 664 | Telmisartan |
| 665 | Telmisartan with amlodipine |
| 666 | Telmisartan with hydrochlorothiazide |
| 667 | Temazepam |
| 668 | Temozolomide |
| 669 | Tenecteplase |
| 670 | Tenofovir with emtricitabine |
| 671 | Tepotinib |
| 672 | Terbinafine |
| 673 | Terbutaline |
| 674 | Teriflunomide |
| 675 | Teriparatide |
| 676 | Testosterone |
| 677 | Tetrabenazine |
| 678 | Tetracosactide |
| 679 | Theophylline |
| 680 | Thiamine |
| 681 | Thyrotropin alfa |
| 682 | Tiagabine |
| 683 | Ticagrelor |
| 684 | Tildrakizumab |
| 685 | Timolol |
| 686 | Tioguanine |
| 687 | Tiotropium |
| 688 | Tiotropium with olodaterol |
| 689 | Tirofiban |
| 690 | Tobramycin |
| 691 | Tocilizumab |
| 692 | Tofacitinib |
| 693 | Tolvaptan |
| 694 | Topiramate |
| 695 | Toremifene |
| 696 | Tramadol |
| 697 | Trametinib |
| 698 | Trandolapril |
| 699 | Trandolapril with verapamil |
| 700 | Tranexamic acid |
| 701 | Tranylcypromine |
| 702 | Trastuzumab |
| 703 | Travoprost |
| 704 | Travoprost with timolol |
| 705 | Triamcinolone |
| 706 | Triamcinolone with neomycin, gramicidin and nystatin |
| 707 | Trientine |
| 708 | Trifluridine with tipiracil |
| 709 | Triglycerides ‑ medium chain, formula |
| 710 | Triglycerides, long chain with glucose polymer |
| 711 | Triglycerides, medium chain |
| 712 | Triglycerides, medium chain and long chain with glucose polymer |
| 713 | Trihexyphenidyl |
| 714 | Trimethoprim |
| 715 | Trimethoprim with sulfamethoxazole |
| 716 | Triptorelin |
| 717 | Tropisetron |
| 718 | Tyrosine with carbohydrate |
| 719 | Umeclidinium |
| 720 | Umeclidinium with vilanterol |
| 721 | Upadacitinib |
| 722 | Ursodeoxycholic acid |
| 723 | Ustekinumab |
| 724 | Valaciclovir |
| 725 | Valine with carbohydrate |
| 726 | Valproic acid |
| 727 | Valsartan |
| 728 | Valsartan with hydrochlorothiazide |
| 729 | Vancomycin |
| 730 | Varenicline |
| 731 | Vedolizumab |
| 732 | Vemurafenib |
| 733 | Venetoclax |
| 734 | Venlafaxine |
| 735 | Verapamil |
| 736 | Vericiguat |
| 737 | Vigabatrin |
| 738 | Vildagliptin |
| 739 | Vildagliptin with metformin |
| 740 | Vinorelbine |
| 741 | Vismodegib |
| 742 | Vitamins, minerals and trace elements formula |
| 743 | Vitamins, minerals and trace elements with carbohydrate |
| 744 | Voriconazole |
| 745 | Vorinostat |
| 746 | Vosoritide |
| 747 | Warfarin |
| 748 | Whey protein formula supplemented with amino acids, long chain polyunsaturated fatty acids, vitamins and minerals, and low in protein, phosphate, potassium and lactose |
| 749 | Whey protein formula supplemented with amino acids, vitamins and minerals, and low in protein, phosphate, potassium and lactose |
| 750 | Zanubrutinib |
| 751 | Ziprasidone |
| 752 | Zoledronic acid |
| 753 | Zolmitriptan |
| 754 | Zonisamide |
| 755 | Zuclopenthixol decanoate |

Schedule 2—Repeals

National Health (Continued Dispensing – Emergency Measure) Determination 2023

1 The whole of the instrument

Repeal the instrument.

Endnotes

Endnote 1—About the endnotes

The endnotes provide information about this compilation and the compiled law.

The following endnotes are included in every compilation:

Endnote 1—About the endnotes

Endnote 2—Abbreviation key

Endnote 3—Legislation history

Endnote 4—Amendment history

**Abbreviation key—Endnote 2**

The abbreviation key sets out abbreviations that may be used in the endnotes.

**Legislation history and amendment history—Endnotes 3 and 4**

Amending laws are annotated in the legislation history and amendment history.

The legislation history in endnote 3 provides information about each law that has amended (or will amend) the compiled law. The information includes commencement details for amending laws and details of any application, saving or transitional provisions that are not included in this compilation.

The amendment history in endnote 4 provides information about amendments at the provision (generally section or equivalent) level. It also includes information about any provision of the compiled law that has been repealed in accordance with a provision of the law.

**Editorial changes**

The *Legislation Act 2003* authorises First Parliamentary Counsel to make editorial and presentational changes to a compiled law in preparing a compilation of the law for registration. The changes must not change the effect of the law. Editorial changes take effect from the compilation registration date.

If the compilation includes editorial changes, the endnotes include a brief outline of the changes in general terms. Full details of any changes can be obtained from the Office of Parliamentary Counsel.

**Misdescribed amendments**

A misdescribed amendment is an amendment that does not accurately describe how an amendment is to be made. If, despite the misdescription, the amendment can be given effect as intended, then the misdescribed amendment can be incorporated through an editorial change made under section 15V of the *Legislation Act 2003*.

If a misdescribed amendment cannot be given effect as intended, the amendment is not incorporated and “(md not incorp)” is added to the amendment history.

Endnote 2—Abbreviation key

|  |  |
| --- | --- |
| ad = added or inserted | o = order(s) |
| am = amended | Ord = Ordinance |
| amdt = amendment | orig = original |
| c = clause(s) | par = paragraph(s)/subparagraph(s) |
| C[x] = Compilation No. x | /sub‑subparagraph(s) |
| Ch = Chapter(s) | pres = present |
| def = definition(s) | prev = previous |
| Dict = Dictionary | (prev…) = previously |
| disallowed = disallowed by Parliament | Pt = Part(s) |
| Div = Division(s) | r = regulation(s)/rule(s) |
| ed = editorial change | reloc = relocated |
| exp = expires/expired or ceases/ceased to have | renum = renumbered |
| effect | rep = repealed |
| F = Federal Register of Legislation | rs = repealed and substituted |
| gaz = gazette | s = section(s)/subsection(s) |
| LA = *Legislation Act 2003* | Sch = Schedule(s) |
| LIA = *Legislative Instruments Act 2003* | Sdiv = Subdivision(s) |
| (md) = misdescribed amendment can be given | SLI = Select Legislative Instrument |
| effect | SR = Statutory Rules |
| (md not incorp) = misdescribed amendment | Sub‑Ch = Sub‑Chapter(s) |
| cannot be given effect | SubPt = Subpart(s) |
| mod = modified/modification | underlining = whole or part not |
| No. = Number(s) | commenced or to be commenced |

Endnote 3—Legislation history

| Name | Registration | Commencement | Application, saving and transitional provisions |
| --- | --- | --- | --- |
| National Health (Continued Dispensing – Emergency Measure) Determination 2023 (PB 137 of 2023) | 21 Dec 2023 (F2023L01742) | Sch 2: 11.59 pm (A.C.T) 31 Mar 2024 (s 1.02(1) item 2) Remainder: 4.06 pm (A.C.T.) 21 Dec 2023 (s 1.02(1) item 1) |  |
| National Health (Continued Dispensing – Emergency Measure) Amendment Determination (No. 1) 2024 (PB 20 of 2024) | 28 Feb 2024 (F2024L00239) | 29 Feb 2024 (s 2(1) item 1) | — |

Endnote 4—Amendment history

| Provision affected | How affected |
| --- | --- |
| **Part 1** |  |
| s 1.02 | am F2024L00239 |
|  | rep LA s 48D |
| s 1.04 | rep LA s 48C |
| **Schedule 2** |  |
| Schedule 2 | rep LA s 48C |